A multicentre UK study of adults with inflammatory bowel disease (IBD) compared with healthy individuals as controls assessed the effect of several immunosuppressive IBD treatments on immune responses to SARS-CoV-2 vaccines. Participants who had all received two doses of the Pfizer–BioNTech BNT162b2, the Moderna mRNA-1273 or the AstraZeneca–University of Oxford ChAdOx1 nCoV-19 vaccines were recruited (n = 483), and antibody responses were measured 53–92 days after second vaccine dose. In patients with IBD, the antibody response of SARS-CoV-2 vaccines did vary according to immunosuppressive drug regimen and was lower in patients receiving infliximab, infliximab plus thiopurines, or tofacitinib than in healthy individuals as controls.
Authors: James L Alexander; Nicholas A Kennedy; Hajir Ibraheim; Sulak Anandabaskaran; Aamir Saifuddin; Rocio Castro Seoane; Zhigang Liu; Rachel Nice; Claire Bewshea; Andrea D'Mello; Laura Constable; Gareth R Jones; Sharmili Balarajah; Francesca Fiorentino; Shaji Sebastian; Peter M Irving; Lucy C Hicks; Horace R T Williams; Alexandra J Kent; Rachel Linger; Miles Parkes; Klaartje Kok; Kamal V Patel; Julian P Teare; Daniel M Altmann; Rosemary J Boyton; James R Goodhand; Ailsa L Hart; Charlie W Lees; Tariq Ahmad; Nick Powell Journal: Lancet Gastroenterol Hepatol Date: 2022-02-04